Skip to main content

Table 2 Dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

From: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Nature of event Events Time to event (months) Events during treatment Major events Histology DMARDsb Prednisoloneb Permanent withdrawal of anti-TNF-αc
  No. (%) Mediana Range No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Infection 33 (25.8) 9.1 1.1–61.1 24 (73) 0 5 (15) 20 (61) 21 (64) 4 (12)
Eczema 20 (15.6) 7.1 0.2–49.9 16 (80) 1 (5) 4 (20) 8 (40) 7 (35) 3 (15)
Drug-related eruption 15 (11.7) 1.9 0.1–18.8 15 (100) 1 (7) 12 (80) 6 (40) 6 (40) 7 47)
Ulcers 9 (7.0) 13.6 0.3–52.5 3 (33) 1 (11) 2 (22) 7 (78) 4 (44) 1 (11)
Skin tumor, benign 7 (5.5) 12.9 2.0–18.1 7 (100) 0 2 (29) 5 (71) 4 (57) 0
Skin tumor, malignant 5 (3.9) 4.5 1.1–38.0 4 (80) 0 5 (100) 2 (40) 2 (40) 1 (20)
Xerosis cutis 6 (4.7) 8.9 4.2–26.3 6 (100) 0 1 (16) 4 (67) 1 (17) 1 (17)
Vasculitis 5 (3.9) 12.0 1.5–49.9 4 (80) 0 4 (80) 3 (60) 5 (100) 1 (20)
Actinic keratosis 5 (3.9) 26.3 4.5–112.9 2 (40) 0 3 (60) 5 (100) 2 (40) 0
CVI/varices 4 (3.0) 24.0 1.7–33.6 3 (75) 0 0 3 (75) 2 (50) 0
Psoriasis/psoriasiform 3 (2.3) 15.5 8.4–50.1 3 (100) 0 3 (100) 0 2 (67) 1 (33)
Edema 3 (2.2) 8.2 4.0–39.6 2 (67) 0 1 (33) 1 (33) 1 (33) 0
Stasis dermatitis 3 (2.2) 17.5 14.6–42.1 3 (100) 0 1 (33) 1 (33) 1 (33) 0
Seborrheic dermatitis 2 (1.5) 0.4, 19.8 2 (100) 0 0 0 0 0
Other event 8 (6.0) 5.0 1.9–25.9 6 (75) 0 4 (50) 4 (50) 2 (25) 2 (25)
Total 128 (100) 9.1 0.1–112.9 100 (78) 3 (2) 47 (37) 69 (54) 60 (47) 21 (16)
  1. aMedian and range given for three cases or more; individual data given for two cases or fewer. bNumber of patients with concomitant DMARDs and prednisolone at the time of event. cPermanent discontinuation of TNF-α-blocking therapy because of the event. DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor.